Experts are concerned about overuse of macrolides leading to increased prevalence of macrolide-resistant pathogens that has major implications for the treatment of mainly upper respiratory tract infections (URTI). Resistance to the macrolide antibiotics (e.g., erythromycin, clarithromycin, and azithromycin) escalated in tandem with penicillin resistance [9, 10] . In addition, macrolide resistance can develop independently of penicillin resistance [11, 12] . In many parts of the world, macrolide-resistant Streptococcus pneumoniae is more common than PRSP [13, 14] . Cefotaxime and ceftriaxone are the most active cephalosporines against pneumococci [11] . Despite marked escalation in PNSP, rates of resistance to cefotaxime (MICs ≥ 2 μg/mL) globally remain low (1 to 7%) [15, 16] .
No previous analyses have attempted to determine optimal therapy for URTIs on the basis of cost-minimization models and the prevalence of antimicrobial resistance among respiratory pathogens in Slovakia. This investigation compares macrolides and cephalosporines for empirical therapy of URTIs. We performed a cost-minimization and sensitivity analysis comparing cephalosporines and macrolides to determine the threshold level of antimicrobial resistance for which each of these antibiotics becomes cost-minimizing. 
RESULTS

For
METHODS
To determine the threshold level of macrolides and cephalosporines resistance among community respiratory pathogens that would make cephalosporines cost-minimizing, we employed a decision tree model using the TreeAge Pro software (Version 2013). The model is based on a clinical pathway model of acute bacterial rhinosinusitis treatment [17] . Model uses a payer perspective for the study. To obtain information on clinical outcomes and cost of URTIs, a systematic review of the literature and local sources was performed. The cost-minimization model of URTIs treatment on scenarios was derived from the review of the literature and published models [18, 19] . In the model, infection would resolve with initial therapy or would fail to respond to initial therapy ( Figure  1 ). In the latter case, the URTI would resolve after continuation with that treatment or the original antibiotic treatment would be extended. Potential complications of clinical non-response included hospitalization due to rhinosinusitis complications. The decision analysis model for the comparison of macrolide and cephalosporines treatment is shown in Figure 1 . Because cephalosporines resistance (3 rd generation) has remained relatively stable in Slovakia and Europe, cephalosporines resistance was held constant at 0,5% for the model [15, 16] .
COSTS
Costs used in this model were based on the systematic review of the literature and a survey of costs derived from national and local sources (Table 1) . Antibiotic cost was defined as the lowest reimbursement amount of all present products in each selected molecule [20] . Costs of hospitalization were compiled from a national survey and incorporated the average cost of a single hospitalization. Costs of physician visits were derived from the literature [21].
Probabilities for clinical events were obtained from multiple published estimates with use of the mean value as the point estimate in the model. Clinical response was derived from prospective clinical trials, investigations and from local clinical experts experience where we had less than 1 source.
Sensitivity analyses
One-way sensitivity analyze was performed for the comparison of mean cost of empirical treatment with macrolides vs. cephalosporines. In addition, a 2-way sensitivity analysis was performed to determine how changing the values of each cost and probability in the model would affect the cost-minimization threshold (Table 1) .
CONCLUSIONS
Longer duration of antibiotic treatment might have disadvantages, compared with equally effective shorter duration treatment (offered for example by 3 rd generation cephalosporines), including higher toxicity, promotion of bacterial drug resistance and greater overall economic burden. Regarding toxicity, the most common adverse events reported in the RCTs included in Falagas et al (2008) meta-analysis were gastrointestinal in nature, consisting primarily of diarrhoea and nausea/vomiting. Although these are frequently non-severe, they can cause considerable patient discomfort and decrease compliance with therapy [22] . Prolonged antimicrobial therapy is often associated with poor patient compliance after the resolution of symptoms or because of toxicity; a fact that may lead to inappropriately low drug levels, thus facilitating the emergence of resistance [23, 24] . Last, but not least, the economic benefits of shortened effective treatment should not be disregarded, since at a community level the cost of even 2 extra days of therapy may be appreciable [25] . We believe we have performed the first cost-based model and sensitivity analysis to determine what level of macrolide resistance in the community could trigger a switch of empirical therapy for URTIs from macrolides to cephalosporines in Slovakia. Our investigation also employ decision analysis to explore the relationship between antimicrobial resistance and clinical decision making in URTIs. From a payer perspective, cephalosporines appears to be a reasonable alternative to macrolides for empirical treatment of URTIs, especially given the current prevalence of macrolides resistance among S. pneumoniae in community that reached 30% level [26] . 
